PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
Stocks in this Quantisnow insightHealth Care
Historical context for JUNS
Across the 12 sessions after earlier JUNS headlines, the stock closed higher 7 times and lower 4 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | JUNS | SPY |
|---|---|---|---|
| May 20, 2026 | Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | -36.0% | +1.0% |
| Apr 7, 2026 | Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board | +2.6% | +0.0% |
| Mar 31, 2026 | Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 | +15.8% | +2.9% |
| Mar 2, 2026 | Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 | -4.4% | +0.1% |
| Feb 25, 2026 | Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago | +0.9% | +0.8% |
| Feb 23, 2026 | Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution | +0.0% | -1.0% |
Quantisnow market dataNASDAQ
JUNS
Jupiter Neurosciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for JUNS
Full JUNS profile on Quantisnow Follow JUNS and get a push notification the moment its next story breaks.